Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Childhood acute lymphoblastic leukaemia chemotherapy intensification trial
ACTRN12607000302459Phase 3Completed
- Sponsor
- ANZCHOG
- Start
- Sep 2002
- Modality
- Small Molecules, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label trial of prednisolone, vincristine, asparaginase escherichia coli, daunorubicin, methotrexate and 13 more in acute lymphoblastic leukemia (ALL) (2 arms), sponsored by ANZCHOG. Primary endpoint: Complete remission rate. Started Sep 2002; status: completed.
02
Drugs
prednisolonevincristineasparaginase escherichia colidaunorubicinmethotrexate
03
Conditions
acute lymphoblastic leukemia (ALL)
Beyond the preview
Go deeper on ACTRN12607000302459.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12607000302459.